Rosiglitazone increased surface and total protein expression in a dose-dependent manner across multiple UC cells (Fig. 2c–g, Supplementary Fig. 2a–f), without affecting TROP2, another surface protein target expressed in UC and other cancers (Fig. 2h)29,30. This evidence concerns the gene TACSTD2 and cancer.